C.1993366461464 137
Tuttavia, lintento quello di trarne ulteriori benefici (recupero e supporto alla perdita di peso), anche lassunzione dopo lesercizio fisico pu essere efficace
2020 Aug;42(4):617-625
(532) analyzed documents from the National Diet and Nutrition Survey Rolling Programme (NDNS RP) 20082014 to evaluate polyphenol consumption among the UK population
Mir SM, Aliarab A, Goodarzi G, Shirzad M, Jafari SM, Qujeq D, et al
Retatrutide Clinical Research Findings The clinical development program for retatrutide has produced compelling data across multiple research endpoints: Weight Loss Efficacy: Phase 2 trials showed dose-dependent weight reduction ranging from 8.7% at the lowest dose to 24.2% at the highest dose over 48 weeks Metabolic Improvements: Participants demonstrated improvements in glycemic control, lipid profiles, and blood pressure measurements Safety Profile: Gastrointestinal effects (nausea, vomiting, diarrhea) were the most common adverse events, occurring in 60-80% of participants but generally rated as mild to moderate in severity Sustained Effects: Weight loss continued throughout the trial period without evidence of plateau, suggesting ongoing metabolic benefits These findings have positioned retatrutide as a leading candidate for advanced metabolic research
